Rollover Study to Continue IMSA101 Treatments in Patients With Advanced Treatment-Refractory Malignancies Previously Enrolled in the Phase I/IIA Safety and Efficacy Study of IMSA101
Latest Information Update: 22 Nov 2024
At a glance
- Drugs IMSA 101 (Primary) ; Immune checkpoint protein inhibitors
- Indications Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImmuneSensor
- 18 Nov 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
- 18 Nov 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
- 10 Oct 2023 Status changed from not yet recruiting to active, no longer recruiting.